DCM
ELOX

DAFNA Capital Management’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

DAFNA Capital Management’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,787
Closed -$375K – 94
2020
Q1 		$375K Sell
4,787
-359
-7% -$58.5K 0.16% 72
2019
Q4 		$1.51M Sell
5,146
-4,229
-45% -$852K 0.52% 46
2019
Q3 		$1.7M Hold
9,375
– – 0.64% 41
2019
Q2 		$3.74M Buy
+9,375
New +$3.95M 1.41% 22

Other funds holding ELOX

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

DAFNA Capital Management's ELOX Position: Q2 2020 in Review

DAFNA Capital Management sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q2 2020, closing a stake of 4,787 shares — an estimated $375K sold.

DAFNA Capital Management first reported a position in ELOX in Q2 2019 and held it in 4 quarters. The position peaked at $3.74M in Q2 2019. 39 funds tracked by Wall St. Rank hold ELOX as of Q2 2020.

  • DAFNA Capital Management reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • DAFNA Capital Management sold 4,787 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $375K.
  • DAFNA Capital Management first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • DAFNA Capital Management's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $3.74M in Q2 2019.
  • 39 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on DAFNA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.